Overview

A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.

Phase:

Phase 2

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Donepezil